title: Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats.
abstract: F-180 is a new, long-acting analog of vasopressin with a selective agonist effect on the vascular V1a receptors, with the advantage of having no effect on renal V2 receptors. F-180 is approximately 20 times more powerful than terlipressin in reducing portal pressure and has less marked systemic effects. The present study investigated the effects of F-180 on the outcome of portal hypertension-related bleeding in hypovolemic rats. Partial portal vein-ligated rats were subjected to portal hypertension-related bleeding by sectioning a first-order branch of the ileocolic vein. After hemodynamic stabilization, a second sectioning of the first-order branch of the ileocolic vein section was performed in the already hypovolemic animals, and either F-180 or placebo was administered. Blood transfusion was adjusted to maintain mean arterial pressure (MAP) gamma > 80 mm Hg. The first section of a first-order branch of the ileocolic vein induced a hemorrhage of similar severity in both groups of rats. After a 2nd sectioning of a first-order branch of the ileocolic vein section, F-180 was more effective than placebo in recovering shock (MAP, 21% +/- 23% vs. 0% +/- 13% in placebo; P <.05), preventing portal pressure (PP) increase during blood transfusion (PP: -1% +/- 19% vs. 47% +/- 65% in placebo; P =.07), reducing transfusion requirements (2.9 +/- 3.3 mL vs. 11.2 +/- 6.0 mL in placebo; P <.01), diminishing the magnitude of collected blood losses (5.1 +/- 2.2 g vs. 12.7 +/-7.7 g in placebo; P <.05), and decreasing the mortality from the portal hypertension-related bleeding (10% vs. 60% in placebo; P <.05). In conclusion, in hypovolemic portal-hypertensive rats during a portal hypertension-related bleeding, F-180 rapidly recovers arterial pressure and decreases transfusion requirements, blood losses, and mortality.
authors.affiliation: Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Spain.
authors.forename: Josephine
authors.initials: J
authors.lastname: Morales
authors.forename: Eduardo
authors.initials: E
authors.lastname: Moitinho
authors.forename: Juan G
authors.initials: JG
authors.lastname: Abraldes
authors.forename: Mercedes
authors.initials: M
authors.lastname: Fernández
authors.forename: Jaime
authors.initials: J
authors.lastname: Bosch
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001803:Blood Transfusion; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy*; D006975:Hypertension, Portal / Q000150:complications*; D008297:Male; D017082:Portal Pressure / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014667:Vasopressins
chemical_list: C110660:F-180 vasoconstrictor peptide; D014662:Vasoconstrictor Agents; D014667:Vasopressins